Published in World J Gastroenterol on July 01, 2003
Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol (2007) 1.02
Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterol J (2014) 0.97
Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol (2007) 0.93
Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines. Tech Coloproctol (2015) 0.92
Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut (2006) 0.89
Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies. Therap Adv Gastroenterol (2011) 0.86
Transient lactose malabsorption in patients affected by symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci (2006) 0.85
Hand-assisted laparoscopic sigmoid resection for diverticular disease: 100 consecutive cases. Surg Endosc (2006) 0.82
Fiber and colorectal diseases: separating fact from fiction. World J Gastroenterol (2007) 0.80
Rifaximin: recent advances in gastroenterology and hepatology. Gastroenterol Hepatol (N Y) (2007) 0.78
New strategies for the management of diverticular disease: insights for the clinician. Therap Adv Gastroenterol (2013) 0.78
Association Between Colonic Diverticulosis and Erectile Dysfunction: A Nationwide Population-Based Study. Medicine (Baltimore) (2015) 0.76
Diverticular disease of the colon: a deficiency disease of Western civilization. Br Med J (1971) 9.82
THE INTRALUMINAL PRESSURE PATTERNS IN DIVERTICULOSIS OF THE COLON. I. RESTING PATTERNS OF PRESSURE. II. THE EFFECT OF MORPHINE. Gut (1964) 7.25
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol (2000) 5.72
Acute diverticulitis. N Engl J Med (1998) 4.16
Treatment of perforated diverticular disease of the colon. Adv Surg (1978) 3.33
THE INTRALUMINAL PRESSURE PATTERNS IN DIVERTICULOSIS OF THE COLON.3. THE EFFECT OF PROSTIGMINE. IV. THE EFFECT OF PETHIDINE AND PROBANTHINE. Gut (1964) 3.03
Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol (1999) 2.79
Practice parameters for the treatment of sigmoid diverticulitis--supporting documentation. The Standards Task Force. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum (2000) 2.77
Natural history of diverticular disease of the colon. Clin Gastroenterol (1975) 2.76
Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol (1975) 2.53
Symptomless diverticular disease and intake of dietary fibre. Lancet (1979) 2.45
Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut (1983) 2.39
Medical progress. Diverticular disease of the colon. N Engl J Med (1980) 2.26
Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Surg Endosc (1999) 2.21
Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet (1977) 2.16
Neuroimmune appendicitis. Lancet (1999) 2.05
Diverticular disease: three studies. Part I--Relation to other disorders and fibre intake. Br Med J (1976) 1.97
Right-sided diverticulosis of the colon. Br J Surg (1971) 1.70
Prospective study of physical activity and the risk of symptomatic diverticular disease in men. Gut (1995) 1.67
A prospective study of diet and the risk of symptomatic diverticular disease in men. Am J Clin Nutr (1994) 1.66
Laparoscopic surgery for diverticulitis. Surg Endosc (1997) 1.64
A role for inflammation in irritable bowel syndrome? Gut (2002) 1.57
Medical and surgical therapy in diverticular disease: a comparative study. Gastroenterology (1976) 1.53
Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs (1995) 1.45
Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial. Br Med J (Clin Res Ed) (1981) 1.44
[Diverticulitis is increasing among the elderly. Significant cause of morbidity and mortality]. Lakartidningen (1997) 1.41
Trends of diverticular disease of the large bowel in a newly developed country. Dis Colon Rectum (1991) 1.29
Damage to the enteric nervous system in experimental colitis. Am J Pathol (1999) 1.25
A critique of "fiber deficiency". Am J Dig Dis (1976) 1.24
PATHOGENESIS OF MULTIPLE DIVERTICULA OF THE SOGMOID COLON IN DIVERTICULAR DISEASE. Acta Chir Scand Suppl (1964) 1.16
A prospective study of alcohol, smoking, caffeine, and the risk of symptomatic diverticular disease in men. Ann Epidemiol (1995) 1.14
Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis (2002) 1.12
Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2000) 1.11
Fecal beta-sitosterol in patients with diverticular disease of the colon and in vegetarians. Scand J Gastroenterol (1978) 1.11
Pathogenesis of colonic diverticula. Br J Surg (2002) 1.10
Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther (1995) 1.09
Elastosis in diverticular disease of the sigmoid colon. Gut (1985) 1.09
An interim report on the production of colonic diverticula in the rabbit. Gut (1972) 1.08
Complicated diverticular disease of the sigmoid colon. An analysis of short and long term outcome in 392 patients. Ann Chir Gynaecol (1979) 1.07
The 5-year natural history of complicated diverticular disease. Br J Surg (1994) 1.06
Acute left colonic diverticulitis in young patients. J Am Coll Surg (1994) 1.04
Movements of the large intestine. Physiol Rev (1966) 1.04
Bowel muscle in diverticular disease. Gut (1966) 1.03
Colonic diverticular disease. Curr Probl Surg (2000) 1.02
Cereal dietary fiber consumption and diverticular disease: a lifespan study in rats. Am J Clin Nutr (1985) 1.01
Diverticular disease of the large bowel in Singapore. An autopsy survey. Dis Colon Rectum (1986) 1.00
Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther (2000) 1.00
Diverticular disease of the colon in a far-eastern community. Dis Colon Rectum (1980) 0.99
Diverticular disease of the large intestine in Northern Norway. Gut (1979) 0.97
Colonic muscle in diverticular disease. Clin Gastroenterol (1986) 0.97
Diverticular disease in the elderly. Gastroenterol Clin North Am (2001) 0.95
HIATUS HERNIA AND DIVERTICULUM OF THE COLON. THEIR LOW INCIDENCE IN KOREA. N Engl J Med (1964) 0.94
Evaluation of the effect of rifaximin in colon diverticular disease by means of lactulose hydrogen breath test. Curr Med Res Opin (1994) 0.93
Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol (1992) 0.92
High fibre diet in symptomatic diverticular disease of the colon. Ann R Coll Surg Engl (1985) 0.91
Usefulness of colonic motility study in identifying patients at risk for complicated diverticular disease. Dis Colon Rectum (1991) 0.90
THE INCIDENCE OF COLONIC DIVERTICULOSIS IN FINLAND AND SWEDEN. Acta Chir Scand (1964) 0.88
Diverticular disease of the colon in black Africa. J R Coll Surg Edinb (1992) 0.84
Putative inflammatory and immunological mechanisms in functional bowel disorders. Baillieres Best Pract Res Clin Gastroenterol (1999) 0.83
Diet and diverticulitis. Br Med J (1968) 0.82
Substance P containing nerve fibers in rectal mucosa of ulcerative colitis. Dis Colon Rectum (1997) 0.81
Axonal damage in Crohn's disease is frequent, but non-specific. J Pathol (1990) 0.81
Diverticular disease. Epidemiology and pharmacological treatment. Drugs Aging (1995) 0.80
Changes in the crude fiber content of the American diet. Am J Clin Nutr (1978) 0.79
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology (2012) 2.83
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut (2006) 2.56
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology (2010) 2.48
Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg (2012) 2.27
Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl (2002) 2.18
Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology (2013) 2.16
An inter- and intra-laboratory comparison of breath ¹³CO₂analysis. Aliment Pharmacol Ther (2003) 2.03
Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol (2008) 1.99
MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One (2009) 1.79
Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol (2010) 1.76
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology (2009) 1.75
Pneumatosis cystoides intestinalis. World J Gastroenterol (2011) 1.44
Health technology assessment agencies: an international overview of organizational aspects. Int J Technol Assess Health Care (2007) 1.39
Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol (2008) 1.31
Silybin and the liver: from basic research to clinical practice. World J Gastroenterol (2011) 1.27
Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology (2010) 1.26
Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Res (2003) 1.25
Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. Cancer Res (2003) 1.20
Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol (2009) 1.18
Inflammatory bowel disease: Moving toward a stem cell-based therapy. World J Gastroenterol (2008) 1.10
Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol (2010) 1.10
Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma. J Gastroenterol (2014) 1.09
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin Cancer Res (2005) 1.04
Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol (2007) 1.02
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol (2008) 1.00
Catheter-related candidemia caused by Candida lipolytica in a patient receiving allogeneic bone marrow transplantation. J Clin Microbiol (2002) 1.00
Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol (2006) 0.97
Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol (2010) 0.97
Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial. World J Gastroenterol (2003) 0.95
13C-urea breath test to assess Helicobacter pylori bacterial load. Helicobacter (2005) 0.95
Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.94
Severe acute autoimmune hepatitis after natalizumab treatment. Dig Liver Dis (2011) 0.94
Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter (2006) 0.94
Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol (2003) 0.94
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol (2003) 0.94
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. Med Chem (2011) 0.93
Micronucleus frequency in human peripheral blood lymphocytes as a biomarker for the early detection of colorectal cancer risk. Mutagenesis (2014) 0.93
Therapeutic effectiveness of echo-guided percutaneous radiofrequency ablation therapy with a LeVeen needle electrode in hepatocellular carcinoma. World J Gastroenterol (2006) 0.92
ESWL for difficult bile duct stones: a 15-year single centre experience. World J Gastroenterol (2010) 0.92
Natural history of small gallbladder polyps is benign: evidence from a clinical and pathogenetic study. Am J Gastroenterol (2009) 0.91
Plasma antioxidant enzymes and clastogenic factors as possible biomarkers of colorectal cancer risk. Mutat Res (2011) 0.91
Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom (2007) 0.91
Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci (2008) 0.89
Ribavirin for chronic hepatitis C: and the mystery goes on. Dig Liver Dis (2010) 0.89
Prevalence of gallstone disease in first-degree relatives of patients with cholelithiasis. World J Gastroenterol (2005) 0.88
Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol (2010) 0.88
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol (2004) 0.88
Focal nodular hyperplasia of the liver after intensive treatment for pediatric cancer: is hematopoietic stem cell transplantation a risk factor? Eur J Pediatr (2011) 0.87
Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs (2011) 0.87
Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy. Scand J Gastroenterol (2006) 0.87
Non-invasive methods can predict oesophageal varices in patients with biliary atresia after a Kasai procedure. Dig Liver Dis (2011) 0.86
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol (2007) 0.85
Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole. World J Gastroenterol (2006) 0.85
Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol (2002) 0.85
The pharmacological management of intrahepatic cholestasis of pregnancy. Curr Clin Pharmacol (2011) 0.84
A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. World J Gastroenterol (2007) 0.84
Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol (2006) 0.83
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. World J Gastroenterol (2009) 0.82
Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. Cytotherapy (2009) 0.82
Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. Arterioscler Thromb Vasc Biol (2004) 0.81
Endoloop-assisted polypectomy for large peduncolated colorectal polyps. Surg Endosc (2007) 0.80
Berberine and its metabolites: relationship between physicochemical properties and plasma levels after administration to human subjects. J Nat Prod (2014) 0.80
High doses of ursodeoxycholic acid up-regulate the expression of placental breast cancer resistance protein in patients affected by intrahepatic cholestasis of pregnancy. PLoS One (2013) 0.80
Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: evidence from the AIFA-BEST observational study. Eur J Clin Pharmacol (2014) 0.80
Is nasal polyposis a determinant of bronchial hyperresponsiveness and altered quality of life in asthmatic subjects? A case-control study. Ann Clin Lab Sci (2006) 0.80
Is it possible to predict the clinical course of gallstone disease? Usefulness of gallbladder motility evaluation in a clinical setting. Am J Gastroenterol (2006) 0.79
Results of endoscopic retrograde cholangiopancreatography in the treatment of biliary tract complications after orthotopic liver transplantation: our experience. Hepatogastroenterology (2007) 0.79
Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol (2015) 0.79